Also trades as: ORMP (NASDAQ) · $vol 1M
ORMP.TA TLV
Oramed Pharmaceuticals Inc.
1W: -6.4%
1M: +7.4%
3M: +16.9%
YTD: +16.9%
1Y: +43.6%
3Y: -57.4%
5Y: +2.1%
₪1,298.00 ($4.44)
+78.00 (+6.39%)
Weekly Expected Move ±8.5%
₪1101
₪1213
₪1325
₪1437
₪1549
Overview
News
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap₪493.4M ($1.7M)
52W Range680-1499
Volume17,585
Avg Volume7,039
Beta1.26
Dividend₪78.58
Analyst Ratings
Company Info
CEONadav Kidron
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2017-07-13
Websiteoramed.com
1185 Avenue of the Americas
New York City, NY 10036
US
New York City, NY 10036
US
844 967 2633
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Recent Insider Trades
No insider trades found